LOS ANGELES, May 19, 2015 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced that Andrew Gengos, Chief
Executive Officer of ImmunoCellular, will present a corporate
overview and business update at the Marcum MicroCap Conference on
Thursday, May 28, 2015 at
10:00 am ET at the Grand Hyatt hotel,
New York, New York.
To access the live audio webcast of the Marcum presentation,
please log on through a link located in the Investors section of
ImmunoCellular's website at www.imuc.com, under the Events &
Presentations tab. A replay of the webcast will be available one
hour after the conclusion of the live event.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. ImmunoCellular has concluded a phase 2 trial of its
lead product candidate, ICT-107, a dendritic cell-based
immunotherapy targeting multiple tumor-associated antigens on
glioblastoma stem cells. ImmunoCellular's pipeline also includes:
ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen
on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell
immunotherapy targeting antigens on ovarian cancer stem cells; and
the Stem-to-T-cell research program which engineers the patient's
hematopoietic stem cells to generate antigen-specific
cancer-killing T-cells. To learn more about ImmunoCellular, please
visit www.imuc.com.
Contact:
For ImmunoCellular Therapeutics, Ltd.
Jane Green.
Investor Relations
415.348.0010
jane@jmgcomm.com
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-to-present-at-marcum-microcap-conference-on-may-28th-300084916.html
SOURCE ImmunoCellular Therapeutics, Ltd.